Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16633648 | 0.94 | SCN8A (0.47) | SCN8ANOS1MPODPP7IDH1 | |
| SCHEMBL16633108 | 0.92 | SCN8A (0.40) | SCN8ANOS1IDH1TBXA2RHDAC1 | |
| SCHEMBL16633107 | 0.80 | TBXA2R (0.38) | HTR2ATBXA2RCNR1 | |
| SCHEMBL2964170 | 0.77 | TBXA2R (0.40) | NOS1IDH1TBXA2R | |
| SCHEMBL16634085 | 0.77 | KCNN4 (0.35) | IDH1TBXA2R | |
| SCHEMBL16633106 | 0.75 | GFER (0.45) | KDM4ETBXA2R | |
| SCHEMBL18917603 | 0.74 | TDP1 (0.40) | — | |
| SCHEMBL16633649 | 0.74 | KCNN4 (0.37) | IDH1TBXA2R | |
| SCHEMBL11922712 | 0.73 | SCN8A (0.64) | SCN8ANOS1DPP7 | |
| SCHEMBL816601 | 0.72 | GAA (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238632-B2 | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | NHWA Pharma, Corporation (CN) | 2016-01-19 | — | — | US | disclosed |
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105399-A1 | 3-CYANOANILINOALKYLARYLPIPERAZINE DERIVATIVE AND USE THEREOF IN PREPARING DRUGS | HTR5A, HTR3C, HTR3A | SCN8A 489/4885NOS1 1614/4885MPO 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.